PharmaEngine, Inc. is a biotechnology company operating under a virtual pharmaceutical company business model. The company focuses on precision cancer therapy, with research areas including DNA damage response and synthetic lethality targets. Its lead product, ONIVYDE, is a microsome formulation of a topoisomerase I inhibitor developed using nanotechnology to treat cancer. The company is also developing PEP08, a new drug candidate currently undergoing Phase I clinical trials for solid tumors. PharmaEngine serves the oncology market, with ONIVYDE approved for use in first-line combination therapy for metastatic pancreatic cancer.

Summarised from the company's own disclosures

Industry Biotechnology Homepage pharmaengine.com
Sector Healthcare IR page pharmaengine.com/investors
Tags
oncology, nanotechnology, topoisomerase inhibitors, precision medicine, clinical trials, pancreatic cancer, ONIVYDE, PEP08
Press page —

Metrics

Valuation  
Market cap NT$ 7.241B
Market cap (USD) $ 219.771M
P/E 13.33
PEG 1.98
P/BV 1.43
P/S 6.89
P/OCF 15.85
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 7.5%
ROI 7.9%
ROIC 6.6%
Profit margin 42.5%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 6.7%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score -18.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 911.416M 2.523B 767.669M 654.383M 654.835M 1.056B 314.04M 293.43M 853.677M 1.135B 507.244M 228.986M 37.4M
Net profit 387.641M 1.751B 274.65M 318.783M 426.031M 604.281M 42.55M 129.362M 387.063M 689.625M 394.022M 123.592M -117.848M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 70.4 — — — — — — — — — — — —
P/S 11.1 — — — — — — — — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

公告本公司115年第三季財務報告 Bull 0 Bear 5 Results

Prompts

PharmaEngine, Inc. (ticker 4162.TWO), listed in Taiwan.

ETFs Holding PharmaEngine, Inc.

ETF Weight in ETF Shares Market value As of
AVEE 0.01% 10,000 $ 15.991K Nov 16, 2026
DFEV 0.00% 47,000 $ 75.555K Nov 12, 2026
DFSE 0.00% 11,000 $ 17.683K Nov 12, 2026
DFEM 0.00% 121,000 $ 194.513K Nov 12, 2026
DFAE 0.00% 77,000 $ 123.781K Nov 12, 2026
DFAX 0.00% 68,000 $ 109.313K Nov 12, 2026
AVEM 0.00% 65,000 $ 103.942K Nov 16, 2026
AVES 0.00% 2,000 $ 3,198.20 Nov 16, 2026
AVXC 0.00% 5,000 $ 7,995.51 Nov 16, 2026